Principal Financial Group Inc Summit Therapeutics Inc. Transaction History

Principal Financial Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	BUY	$6.89 - $31.93 $151,676 - $702,907	22,014 Added 60.92%	58,147 $1.27 Million
Q2 2024 Jul 29, 2024	BUY	$2.39 - $10.92 $49,121 - $224,438	20,553 Added 131.92%	36,133 $281,000
Q1 2024 Apr 29, 2024	BUY	$2.55 - $5.07 $5,615 - $11,164	2,202 Added 16.46%	15,580 $64,000
Q4 2023 Feb 07, 2024	BUY	$1.67 - $2.83 $2,160 - $3,662	1,294 Added 10.71%	13,378 $34,000
Q3 2023 Nov 02, 2023	SELL	$1.54 - $2.42 $2,456 - $3,859	-1,595 Reduced 11.66%	12,084 $22,000
Q2 2023 Aug 07, 2023	BUY	$1.32 - $2.81 $18,056 - $38,437	13,679 New	13,679 $34,000

192

75.8M

2.01M

2.84M

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.6B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.